Use of omalizumab is associated with improvement of pruritic skin disorders induced by immune checkpoint inhibitors: A retrospective cohort from the European Task Force of Dermatology for Cancer patients.

Francesc Alamon-Reig Xavier Bosch-Amate Priscila Giavedoni Vasiliki Nikolaou Cristina Mangas Zoe Apalla Ander Mayor Chrysa Oikonomou Michela Starace Vincent Sibaud Cristina Carrera

J Am Acad Dermatol

Department of Dermatology, Hospital Clínic de Barcelona, FRCB, Universitat de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain. Electronic address:

Published: February 2024

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jaad.2023.10.012	DOI Listing

Publication Analysis

Top Keywords

omalizumab associated

associated improvement

improvement pruritic

pruritic skin

skin disorders

disorders induced

induced immune

immune checkpoint

checkpoint inhibitors

inhibitors retrospective

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!